Can broad-spectrum antivirals treat multiple viral infections?

How can one drug work against many different viruses?

Broad-spectrum antivirals exploit a fundamental weakness: many viruses rely on the same host cell processes or share similar structural features. Instead of targeting a unique viral protein (like the flu's neuraminidase), these drugs hit a common target. One major strategy is targeting the host cell itself—a 'host-targeting antiviral' (HTA). For instance, ebselen works by inhibiting the host enzyme inositol monophosphatase (IMPA), which viruses hijack to replicate. In lab tests, ebselen suppressed five different viruses (dengue, Zika, chikungunya, influenza A, and enterovirus 71), and when researchers silenced the IMPA gene, virus production dropped, confirming the mechanism [3]. Another HTA approach targets cyclophilin A (CypA), a host protein that many viruses, including hepatitis C, HIV, and coronaviruses, need to replicate. Inhibitors of CypA are being repurposed as broad-spectrum agents [8].

A second strategy is to attack the virus's outer envelope—a fatty membrane that many viruses (including SARS-CoV-2, influenza, and herpes) share. Peptides like AR-23, derived from frog skin, and optimized versions of scorpion venom peptide mucroporin-M1, physically disrupt these envelopes. AR-23 was active against enveloped viruses (HSV-1, measles, SARS-CoV-2) but not against non-enveloped viruses, confirming its mechanism [6]. The optimized mucroporin-M1 peptides showed potent 'virucidal' effects against enveloped RNA and DNA viruses from the Flaviviridae and Herpesviridae families, with minimal toxicity to human cells [9]. Even nanomaterials like graphene quantum dots (GQDs) work this way: their amphiphilic properties destroy viral membranes regardless of virus type, suppressing both SARS-CoV-2 and influenza virus infection and replication in cell and mouse models [10].

How well do these drugs actually work in real tests?

The evidence is strongest in cell cultures and animal models, with human trials still limited. A systematic review of 60 studies on plant-based compounds found that flavonoids like quercetin and kaempferol inhibited viral protease and polymerase with IC50 values of 2–12 µM (a measure of potency—lower numbers mean less drug is needed). Terpenoids like glycyrrhizin blocked spike-ACE2 binding and viral fusion by up to 80% in cell tests [1]. These are promising numbers, but the review notes a critical gap: 'a lack of clinical validation' in humans [1].

In animal models, results are more concrete. A 2026 study on 4'-fluorouridine (4'-FlU), a broad-spectrum antiviral against many RNA viruses, tested it in mice infected with Venezuelan equine encephalitis virus (VEEV). Even when the virus developed mutations that reduced susceptibility to the drug in cell culture, treatment with 4'-FlU still 'alleviated severe disease and prevented lethality' in the mice [2]. Another study tested a peptide called HR2P against infectious bronchitis virus (IBV) in chickens. The peptide reduced viral replication by 100- to 1000-fold across four different virus strains and, when given early, lowered illness and death in the birds [4]. These animal studies show that broad-spectrum antivirals can work in living organisms, not just in a dish.

For human-ready evidence, the most advanced example is the repurposing of maraviroc, a CCR5 antagonist originally for HIV, which is now a proven HTA [7]. However, most of the compounds discussed here—ebselen, AR-23, mucroporin-M1, GQDs—are still in preclinical or early clinical stages. The 2023 review in the Journal of Clinical Investigation emphasizes that while the need is urgent, 'most approved antiviral therapeutics target proteins encoded by a single virus,' and broad-spectrum drugs face hurdles in development and regulatory approval [5].

What are the downsides or limitations?

The biggest limitation is that most broad-spectrum antivirals are not yet proven in humans. The plant compound review explicitly states that 'a lack of clinical validation and inconsistency in the standardization of phytochemicals are critical issues' [1]. Even promising candidates like 4'-FlU can face resistance: the VEEV study found that mutations in the viral polymerase arose 'quickly in vitro,' though the drug still worked in mice [2]. This means that while broad-spectrum drugs may be harder to resist than single-target drugs, resistance is still possible.

Another limitation is specificity. Drugs that target host cells (HTAs) can cause side effects because they interfere with normal cell functions. For example, ebselen inhibits IMPA, which is involved in cell signaling, so its long-term safety needs careful study [3]. Similarly, peptides that disrupt viral envelopes might also damage healthy cell membranes if not precisely targeted, though the optimized mucroporin-M1 peptides showed 'minimal cytotoxicity' in early tests [9]. Finally, some broad-spectrum agents only work against enveloped viruses. AR-23 and mucroporin-M1 were inactive against non-enveloped viruses like poliovirus [6][9], meaning they are not truly universal. The search for truly universal antivirals continues, with researchers exploring host immune pathways like the RBM25/RC3H1-Rab22a axis, which restricts viral entry for both RNA and DNA viruses [11].

About These Sources

This answer is built on 11 peer-reviewed studies — published from 2022 to 2026, 7 from 2024 or later, 6 in Q1 journals, collectively cited 183 times — selected as the most relevant from 15 studies that passed quality screening, drawn from 52 papers retrieved from a database of over 500 million.

Sources used in this answer

Related research questions